Sunteți pe pagina 1din 6

Introducere

1. 111= Dr. Haras Monica Andreia, 2012, Particularități ale osteoporozei la pacienții cu
tireotoxicoze, Teză de doctorat - rezumat

2. 5= Manuela Russu, 2007, Seria Ghiduri Clinice pentru Obstretică și Ginecologie.


Terapia menopauzei

3. 10= Corina Cristina Morcov, 2012, Influenţa compoziţiei corporale şi a greutăţii asupra
masei osoase. Obezitatea şi densitatea minerală osoasă, Lucrare doctorat, p.132-144

1. 4= Prof. Dr. Eusebie Zbranca, 2008, Endocrinologie: ghid de diagnostic și tratament


în bolile endocrine, Ediția a III-a, p.207-225,382-389

Cap 1

27= Haulică I. Fiziologie umană, ediția a III-a. București, ed. Polirom,2007, 664-667.

35= Jerca L, Ungureanu D. Biochimia hormonilor, ed. Terra Nostra, Iași 2001, 194-204.

50= Patel S, Homaei A, Raju AB, Meher BR. Estrogen: The necessary evil for human
health, and ways to tame it. Biomedicine & Pharmacotherapy. 2018 Jun30;102:403-11.

76= Zbranca E, Mogoș V, Găleșanu C, Vulpoi C, Endocrinologie,Ghid de diagnostic și


tratament în bolile endocrine, ed. Polirom,2008,345-358.

11= Chang MS. Dual roles of estrogen metabolism in mammary carcinogenesis. BMB
reports. 2011;44(7):423-34.

53= Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by


conjugation. JNCI Monographs. 2000 Jul 1;2000(27):113-24.

51= Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F. Estrogen receptors alpha (ERα)
and beta (ERβ): subtype-selective ligands and clinical potential. Steroids. 2014 Nov15;90:13-
29.
69= Wang ZY, Yin L. Estrogen receptor alpha-36 (ER-α36): A new player in human breast
cancer. Molecular and cellular endocrinology. 2015 Dec 15;418:193-206.

23= Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocrine
reviews. 2007 Oct 4;28(7):726-41.

Hăulică Haulică I. Fiziologie umană, ediția a III-a. București, ed. Polirom,2007, 664-667.

Cap 2

os

1. Zbranca

2. 2 Prof. Univ. Dr. Paulina Ciurea, Conf. Univ. Dr. Anca Roșu, Prep. Univ. Dr.
Anca Mușetescu, Prep. Univ. Dr. Florentin Vreju, 2007, Reumatologie, p. 415-439
3. Williams KB & DeLuca HF. Characterization of intestinal phosphate absorption using
a novel in vivo method. Am.J.Physiol Endocrinol.Metab 2007 292 E1917-E1921.
4. 2. Shoback D, Sellmeyer D & Bikle DD. Metabolic Bone Disease. In Greenspan's
basic and clinical endocrinology, ch. 8, pp 227-285. Eds D Gardner & D Shoback: Mc
Graw Hill, 2011.
5. 3. Feldman D, DJ M, A K & E B. Vitamin D: Biology, Action, and Clinical
Implications. In Osteoporosis, edn 2 nd, ch. 13, pp 317-382. Eds R Marcus, D
Feldman, N A & C Rosen: Elsevier, 2001.
6. 4. Clarke B. Normal bone anatomy and physiology. Clin.J.Am.Soc.Nephrol. 2008 3
Suppl 3 S131-S139.
7. 5. Burr DB. Targeted and nontargeted remodeling. Bone 2002 30 2-4.
8. 6. Bartl R & Frisch B. Biology of bone. In Osteoporosis, edn 2nd, ch. 2, pp 7-28. Eds
R Bartl & B Frisch: Springer, 2009.
9. 7. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R
& National Osteoporosis F. Clinician's Guide to Prevention and Treatment of
Osteoporosis. Osteoporos Int 2014 25 2359-2381

Osteoporoză

1.Cîrstoiu C. Osteoporoza în menopauză. Ed. II, Ed. Univ. „Carol Davila” București, 2013.
2. Cummings SR, Melton III LJ. Epidemiology and outcomes of osteoporotic fractures.
Lancet 2002;359:1761-7.

3. WHO Study Group. Assessment of fracture risk and its application to postmenopausal
osteoporosis.World Health Organ Tech Ser 1984;843.

4. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet


2002;359:1929-36.

5. Close J, Ellis M, Hooper R, Glucksman E, Jackson S, Swift C. Prevention of falls in the


elderly trial (PROFET): a randomised controlled trial. Lancet 1999;353:93-7.

6. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and
adolescents: a review of controlled trials. Bone, 2007;40(1):14- 27.

7. Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin
Rheumatol 2005; 19:1007-19.

8. Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr Opinion


Rheumatol 2005; 17:456-61.

1. 9 . Prof. Dr. Eusebie Zbranca, 2008, Endocrinologie: ghid de diagnostic și tratament


în bolile endocrine, Ediția a III-a, p.207-225,382-389
10. Kanis JA – Diagnosis of osteoporosis and assessment of fracture risk, Lancet 2002,
359: 1929-1336
11. Dr. Vasile Ionuț Silviu, 2011, Studiul modificărilor masei osoase și ale markerilor
metabolismului osos în osteoporoza tiroxinică. Implicații terapeutice, Lucrare doctorat
– Rezumat, p. 8-11
12 Mazess RB 1987 Bone density in diagnosis of osteoporosis: Thresholds and
breakpoints. Calcif Tissue Int 41: 117-1 18.
12 M. Suta, 2006, Evaluarea fracturilor vertebrale osteoporotice, Romanian Journal of
Rheumatology
13. Dumitrache C, Ionescu B., 2002, Endocrinologie clinică. Ediţia a II-a revizuită şi
completată. Ed. Medicală Naţională, Bucureşti
14. Dumitrache C, Ionescu B., 2002, Endocrinologie clinică. Ediţia a II -a revizuită şi
completată. Ed. Medicală Naţională, Bucureşti
15. Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of
osteoporosis. Am J Med 1994; 646–650.
16. 2. Johnell O., Kanis J.A. (2006) An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726–1733.
17. Kanis,J.A., McCloskey,E.V., Johansson,H., Cooper,C., Rizzoli,R., & Reginster,J.Y.
(2013)European guidance for the diagnosis and management of osteoporosis in
postmenopausal women. Osteoporos.Int. 24, 23-57.
18. Kannus,P., Sievanen,H., Palvanen,M., Jarvinen,T., & Parkkari,J. (2005) Prevention of
fall and consequent injuries in elderly people. Lancet 366, 1885-1893.
19. Ooms,M.E., Roos,J.C., Bezemer,P.D., van der Vijgh,W.J., Bouter,L.M., & Lips,P.
(1995)Prevention of bone loss by vitamin D supplementation in elderly women: a
randomized doubleblindtrial. J.Clin.Endocrinol.Metab 80, 1052-1058.
20. Bischoff-Ferrari,H.A., Dietrich,T., Orav,E.J., & Dawson-Hughes,B. (2004b) Positive
association between 25-hydroxy vitamin D levels and bone mineral density: a
population-based study of younger and older adults. Am.J.Med. 116, 634-639.
21. Bischoff-Ferrari,H.A. (2012) Vitamin D and fracture prevention.
Rheum.Dis.Clin.North Am. 38, 107-113.
22. Dawson-Hughes,B., Mithal,A., Bonjour,J.P., Boonen,S., Burckhardt,P., Fuleihan,G.E.,
Josse,R.G., Lips,P., Morales-Torres,J., & Yoshimura,N. (2010) IOF position
statement: vitamin D recommendations for older adults. Osteoporos.Int. 21, 1151-
1154.
23. Stockton,K.A., Mengersen,K., Paratz,J.D., Kandiah,D., & Bennell,K.L. (2011) Effect
of vitamin D supplementation on muscle strength: a systematic review and meta-
analysis. Osteoporos.Int. 22, 859-871.
24. Consensus Development Conference (1993) Diagnosis, prophylaxis and treatment of
osteoporosis. Am J Med 1994; 646–650.
25. 2. Johnell O., Kanis J.A. (2006) An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726–1733.
26. 3. Melton III L.J., Kallmes D.F. Epidemiology of vertebral fractures: Implications
for vertebral augmentation. Acad radiol. 2006; 13:538-45.
27. 4. Nevitt M.C., Ettinger B., Black D.M. et al. The association of radiologically
detected vertebral fractures with back pain and function: a prospective study. Ann
Intern Med 1998;128:793-800.
28. 5. Kanis J.A., Oden A., Johnell O. et al. The components of excess mortality after
hipfracture. Bone 2003; 32:468–473.
29. 6. Cooper C., Atkinson E.J., Jacobsen S.J., O’Fallon W.M., Melton L.J. A
population base study of survival after osteoporotic fractures. Am J Epidemiol 1993;
137:1001–1005.
30. 7. Kanis J.A., McCloskey E.V., Johansson H. et al. European guidance for the
diagnosis and management of osteoporosis în postmenopausal women. Osteoporos
Int. 2013; 24:23–57. doi: 10.1007/s00198-012-2074-y.
31. 8. Stevenson M., Lloyd Jones M., De Nigris E. et al. A systematic review and
economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide
for the prevention and treatment of postmenopausal osteoporosis. Health Technol
Assess 2005; 9:1–160.
32. 9. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N
Engl J Med 2010; 362:1825.
33. 10. Fedele S., Porter S.R., D‘Aiuto F., et al. Nonexposed variant of bisphosphonate-
associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123:1060.
34. 11. Meunier P.J., Slosman D.O., Delmas P.D., et al. Stronţium ranelate: dose-
dependent effects în established postmenopausal vertebral osteoporosis - a 2-year
randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060.
35. 12. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Stronţium ranelate reduces
the risk of nonvertebral fractures în postmenopausal women with osteoporosis:
Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab
2005; 90:2816.
36. 13. J.M. Kaufman, M. Audran, G. Bianchi et al. Effi cacy and Safety of Stronţium
Ranelate în the Treatment of Osteoporosis în Men. JCEM 2013; 98:592-
601;doi:10.1210/jc.2012-3048.
37. 14. European Medicines Agency. EMEA recommends changes în the product
information for Protelos/Osseor due to the risk of severe hypersensitivity reactions.
Press Release (2007). http://www.emea.
europa.eu/docs/en_GB/document_library/Press_release/2009/11/ WC500015592.pdf.
38. 15. Jonville-Bera A.P., Autret-Leca E. Adverse drug reactions of strontium
ranelate(Protelos(®) în France. Presse Med 2011;40:e453.
39. 16. Osborne V., Layton D., Perrio M., et al. Incidence of venous thromboembolism
în users of stronţium ranelate: an analysis of data from a prescription-event monitoring
study în England. Drug Saf 2010;33:579.
40. 17. Recommendation to restrict the use of Protelos / Osseor (strontium ranelate).
http://www.ema.europa.eu/docs/en_GB/document_library/
Press_release/2013/04/WC500142507.pdf.
41. 18. Neer R.M., Arnaud C.D., Zanchetta J.R. et al. Effect of parathyroid hormone
(1–34) on fractures and bone mineral density în postmenopausal women with
osteoporosis. N Engl J Med 2001; 344:1434–1441.
42. 19. Prince R., Sipos A., Hossain A. et al. Sustained nonvertebral fragility fracture
risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;
20:1507–1513.
43. 20. Nakamura T., Sugimoto T., Nakano Tet al. Randomized Teriparatide (Human
Parathyroid Hormone (PTH) 1-34) Once-Weekly Effi cacy Research (TOWER) trial
for examining the reduction în new vertebral fractures în subjects with primary
osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097–
3106.doi:10.1210/jc.2011-3479.
44. 21. Joel S. Finkelstein, Jason J. Wyland, Benjamin Z. Leder et al. Effects of
Teriparatide Retreatment în Osteoporotic Men and Women. JCEM 2009; 94:2495-
2501; doi:10.1210/jc.2009-0154.

Cap 3

20= Grindler N, Al-Safi Z, Santore N. Menopausal hormone therapy. Menopause and Hormone
Replacement Therapy. 2016 Jul 20;381-384.

65 Swords KE. Hormone Therapy for Menopausal Women in the Primary Care Setting. The
Journal for Nurse Practitioners. 2017 Sep 30;13(8):562-9.

1. Prof. Dr. Mihai Pricop, 2008, Curs de obstretică și ginecologie. Ginecologia, Ediția a
II-a, p.167-176
2. Prof. Dr. Eusebie Zbranca, 2008, Endocrinologie: ghid de diagnostic și tratament în
bolile endocrine, Ediția a III-a, p.207-225,382-389
3. Dr. Andrei Martin, 2006, Osteoporoza postmenopauză - mecanisme patogenice,
Articol din publicația Medicina Modernă, p. 1-5 ============ 9
37= Khosla S, Melton III LJ, Riggs BL. The unitary model for estrogen deficiency and the
pathogenesis of osteoporosis: is a revision needed? Journal of Bone and Mineral Research. 2011
Mar;26(3):441-51.

S-ar putea să vă placă și